Novel drugs and vaccines based on the structure and function of HIV pathogenic proteins including Nef

Annals of the New York Academy of Sciences

Volumn 1056, Issue , 2005, Pages 279-292

  Azad, Ahmed A ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

HIV; Nef; Novel drugs; Pathogenic proteins; Vaccines

Indexed keywords

CD4 ANTIGEN; CELL PROTEIN; DNA FRAGMENT; MELITTIN; NATURAL PRODUCT; NEF ANTIBODY; NEF PROTEIN; PROTEIN ANTIBODY; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS VACCINE;

AMINO TERMINAL SEQUENCE; APOPTOSIS; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CONFERENCE PAPER; CONTROLLED STUDY; CYTOLYSIS; DISEASE COURSE; DRUG USE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LYMPHOID TISSUE; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN INTERACTION; SOLUBILITY; STRUCTURE ACTIVITY RELATION; VACCINATION; VIRUS LOAD; VIRUS PATHOGENESIS;

APOIDEA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 29744461868     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1352.013     Document Type: Conference Paper

References (39)

1. LEVY, J. A. 1993. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57: 183-289.
2. WEI, X. et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
3. HO, D.D. et al. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126.
4. PANTALEO, G. et al. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362: 355-358.
5. EMBERTSON, J. et al. 1993. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362: 359-362.
6. PANTALEO, G. et al. 1994. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol. Rev. 140: 105-130.
7. ASCHER, M.S. et al. 1995. HIV results in the frame. Paradox remains. Nature 375: 196.
8. ANDERSON, R.W. et al. 1998. Direct HIV cytopathicity cannot account for CD4 decline in AIDS in the presence of homeostasis: a worst-case dynamic analysis. Acquired Immun. Defic. Syndr. Hum. Retroviruses 17: 245-252.
9. AZAD, A.A. 2000. Could Nef and Vpr proteins contribute to disease progression by promoting depletion of bystander cells and prolonged survival of HIV-infected cells. Biochem. Biophys. Res. Commun. 267: 677-685.
10. AZAD, A.A. 2000. The possible involvement of HIV accessory Nef and Vpr in bystander cell death and prolonged survival of HIV-infected cells. In Advances in Animal Virology. S. Jameel & L. Villareal, Eds.: 297-307. Oxford & IBH Publishing Co. Pvt. Ltd. New Delhi and Calcutta.
11. MACREADIE, I.G. et al. 1993. Yeast-derived HIV-1 Nef protein lacks G-protein activities. Mol. Biol. (Life Sci. Adv.) 12: 99-105.
12. MACREADIE, I.G. et al. 1993. Expression of HIV-1 nef in yeast: The 27 kDa nef protein is myristylated and fractionates with the nucleus. Yeast 9: 565-573.
13. AZAD, A.A. et al. 1994. Large scale production and characterisation of recombinant human immunodeficiency virus type 1 Nef. J. Gen. Virol. 75: 651-655.
14. CURTAIN, C.C. et al. 1994. Fusogenic activity of amino-terminal region of HIV type 1 Nef protein. AIDS Res. Hum. Retroviruses 10: 1231-1240.
15. GREENWAY, A.L. et al. 1994. Nef27, but not the Nef25 isoform of human immunodeficiency virus-type pNL4.3 down-regulates surface CD4 and IL-2R expression in peripheral blood mononuclear cells and transformed cells. Virology 198: 245-258.
16. GREENWAY, A.L., A.A. AZAD & D. MCPHEE. 1995. Human immunodeficiency virus type 1 Nef protein inhibits activation pathways in peripheral blood mononuclear cells and T-cell lines. J. Virol. 69: 1842-1850.
17. MACREADIE, I.G. et al. 1995. Stress- and sequence-dependent release into the culture medium of HIV-1 Nef produced in Saccharomyces cerevisiae. Gene 162: 239-243.
18. GREENWAY, A., A.A. AZAD, J. MILLS & D. MCPHEE. 1996. Human immunodeficiency virus type 1 Nef binds directly to Lck and mitogen-activated protein kinase, inhibiting kinase activity. J. Virol. 70: 6701-6708.
19. CURTAIN, C.C. et al. 1997. Cytotoxic activity of the amino-terminal region of HIV type 1 Nef protein. AIDS Res. Human Retroviruses 13: 1213-1220.
20. BARNHAM, K.J. et al. 1997. Solution structure of a polypeptide from the N-terminus of the HIV protein Nef. Biochemistry 36: 5970-5980.
21. MACREADIE, I.G. et al. 1997. Cytotoxicity resulting from addition of HIV-1 Nef N-terminal peptides to yeast and bacterial cells. Biochem. Biophys. Res. Commun. 232: 707-711.
22. MACREADIE, I.G. et al. 1998. Expression of HIV-1 nef in yeast causes membrane perturbation and release of the myristylated Nef protein. J. Med. Sci. 5: 203-210.
23. MACREADIE, I.G. et al. 1998. Human immunodeficiency virus type 1 Nef protein causes death in stressed yeast due to determinants near the N-terminus and elsewhere in Nef. Biochem. Mol. Biol. Int. 46: 277-286.
24. CURTAIN, C.C. et al. 1999. Structural requirements for the cytotoxicity of the N-terminal region of HIV Type 1 Nef. AIDS Res. Human Retroviruses 14: 1543-1551.
25. GREENWAY, A.L. et al. 2002. Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis. J. Virol. 76: 2692-2702.
26. KESTLER, H.W. et al. 1991. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65: 651-662.
27. DEACON, N.J. et al. 1995. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270: 988-991.
28. JAMIESON, B.D. et al. 1994. Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity. J.Virol. 68: 3478-3485.
29. GULIZA, R.J. et al. 1997. Deletion of nef slows but does not prevent CD4-positive T-cell depletion in human immunodeficiency virus type 1-infected human-PBL-SCID mice. J. Virol. 71: 4161-4164.
30. SKOWRONSKI, J. et al. 1993. Altered T cell activation and development in transgenic mice expressing the HIV-1 nef gene. EMBO J. 12: 703-713.
31. LINDEMAN, D. et al. 1994. Severe immunodeficiency associated with a human immunodeficiency virus 1 NEF/3′-long terminal repeat transgene. J. Exp. Med. 179: 797-807.
32. HANNA, Z. et al. 1998. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 95: 163-175.
33. MANDELL, C.P. et al. 1999. SIV/HIV Nef recombinant virus (SHIVnef) produces simian AIDS in rhesus macaques. Virology 265: 235-251.
34. SAWAI, E.T. et al. 2000. Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef. J. Virol. 74: 2038-2045.
35. FINKEL, T.H. et al. 1995. Apoptosis occurs predominantly in bystander cells of HIV- and SIV-infected lymph nodes. Nature Med. 1: 129-134.
36. SCHWARTZ, O. et al. 1996. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nature Med. 2: 328-342.
37. COLLINS, K.L. et al. 1998. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391: 397-401.
38. PIQUET, V. et al. 1999. The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors. Immunol. Rev. 168: 51-63.
39. COLLINS, K.L. & D. BALTIMORE. 1999. HIV's evasion of the cellular immune response. Immunol. Rev. 168: 65-74.